ABCL

AbCellera Biologics Inc.

Pharmaceutical Preparations · SIC 2834CIK 1703057Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$75.0M

Net Income FY2025

$(146.0M)

EPS (Basic, as reported)

$-0.49

Net Margin FY2025

-194.9%

ROE FY2025

-15.1%

Total Equity

$967.0M

Shares Out

307M

Business description

AbCellera Biologics Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 12 → 75 +35.7% CAGR

Fiscal yearFY2019FY2020⚑FY2021FY2022FY2023FY2024FY2025

Revenue12233375485382975

Research & development(10)(29)(62)(108)(176)(167)(187)

Selling & marketing(1)(4)(7)(11)(14)(13)—

General & administrative(3)(12)(42)(55)(61)(73)(83)

Total operating expenses(16)(77)(171)(269)(275)(344)(292)

Operating income(4)156204217(237)(315)(217)

Interest & investment income00316423828

Other income (expense), net2215236311440

Pre-tax income(2)158219239(174)(200)(178)

Income tax expense—(39)(66)(81)(28)(38)(31)

Net income(2)119153159(146)(163)(146)

EPS — basic($0.01)$0.53$0.56$0.56($0.51)($0.55)($0.49)

EPS — diluted($0.01)$0.45$0.48$0.50($0.51)($0.55)($0.49)

Shares outstanding — basic (M)151159276285289294299

Shares outstanding — diluted (M)151263318315289294299

⚑ Weighted-average shares changed ×1.74 between FY2020 and FY2021 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.